Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.

Investigators tested a new neoadjuvant immunotherapy to fight prostate cancer using a virus-mimicking drug to activate the ...

A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients ...

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...

City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States with ...

Using PROTECT trial data, investigators assessed the possible benefit of early treatment vs active monitoring for cribriform-positive prostate cancer.

Ten years after his successful treatment at the Fred Hutch proton facility, patient Keith Abbott wrote a thank you note to the staff. Due to a family history of esophageal cancer, Abbott underwent ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in ...

Various imaging modalities show low sensitivity for detecting pelvic lymph node invasion prior to surgery in patients with intermediate risk prostate cancer.

Researchers assess the adequacy of tissue ablation by a cooled laser therapy in patients with localized prostate cancer.

Mercy Medical Center is offering a new, noninvasive treatment option for men with localized prostate cancer using high-intensity focused ultrasound, also known ...

Profound Medical Corp. ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased ...